论文部分内容阅读
目的探讨阿奇霉素序贯疗法对小儿支原体肺炎患者免疫功能、肺功能及趋化因子的影响。方法选取2015年5月—2017年5月收治的支原体肺炎患儿96例,采用随机数字表法将患者分为对照组与观察组各48例。两组均进行针对症状的常规治疗,对照组使用阿奇霉素注射液治疗,观察组采用阿奇霉素序贯疗法治疗。比较两组有效率、不良反应发生率、免疫功能指标、肺功能指标、趋化因子指标。计量资料比较采用t检验,计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果观察组总有效率(95.38%)高于对照组(89.58%),但差异无统计学意义(P>0.05)。观察组不良反应发生率(2.08%)低于对照组(12.5%)(P<0.05)。治疗后两组免疫功能指标、肺功能指标、趋化因子指标均高于治疗前(均P<0.05),但组间比较差异均无统计学意义(均P>0.05)。结论阿奇霉素序贯疗法治疗支原体肺炎可提高患儿免疫功能、降低体内趋化因子含量、改善患者肺功能,且可降低不良反应发生率。
Objective To investigate the effect of sequential therapy with azithromycin on immune function, pulmonary function and chemokines in children with mycoplasmal pneumonia. Methods Ninety-six children with mycoplasmal pneumonia admitted from May 2015 to May 2017 were randomly divided into control group and observation group with 48 cases in each group. The two groups were treated for the conventional treatment of symptoms, the control group treated with azithromycin injection, the observation group treated with azithromycin sequential therapy. The two groups were compared, the incidence of adverse reactions, immune function, lung function, chemokine indicators. Measurement data were compared using t test, count data were compared using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate (95.38%) in observation group was higher than that in control group (89.58%), but the difference was not statistically significant (P> 0.05). The incidence of adverse reactions in the observation group (2.08%) was lower than that in the control group (12.5%) (P <0.05). After treatment, the immune function indexes, lung function indexes and chemokine indexes of the two groups were higher than those before treatment (all P <0.05), but there was no significant difference between the two groups (all P> 0.05). Conclusion Sequential azithromycin treatment of mycoplasma pneumonia can improve children’s immune function, reduce the content of chemokines in vivo, improve lung function, and can reduce the incidence of adverse reactions.